SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007407
Filing Date
2022-05-04
Accepted
2022-05-04 16:31:03
Documents
59
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20220331.htm   iXBRL 10-Q 2552016
2 EX-31.1 algs-ex31_1.htm EX-31.1 21053
3 EX-31.2 algs-ex31_2.htm EX-31.2 21051
4 EX-32.1 algs-ex32_1.htm EX-32.1 11947
5 EX-32.2 algs-ex32_2.htm EX-32.2 11942
  Complete submission text file 0000950170-22-007407.txt   7628414

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT algs-20220331_def.xml EX-101.DEF 171168
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT algs-20220331_lab.xml EX-101.LAB 441519
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT algs-20220331.xsd EX-101.SCH 50202
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT algs-20220331_cal.xml EX-101.CAL 42505
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT algs-20220331_pre.xml EX-101.PRE 303888
53 EXTRACTED XBRL INSTANCE DOCUMENT algs-20220331_htm.xml XML 1195240
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 22892006
SIC: 2836 Biological Products, (No Diagnostic Substances)